Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Cytokinetics Shares Fall as Lou Gehrig’s Drug Fails

Don't Miss Out —
Follow us on:

April 25 (Bloomberg) -- Cytokinetics Inc. tumbled the most ever after its experimental treatment for Lou Gehrig’s disease didn’t meet its goal in a study, the company’s second drug to fail a clinical trial in seven months.

Cytokinetics, with no marketed products, fell 65 percent to $4.59 at the close in New York, after the stock had doubled this year through yesterday.

The compound, called tirasemtiv, failed to show it helped patients with Lou Gehrig’s, or amyotrophic lateral sclerosis, more than a placebo in a mid-stage study, the South San Francisco, California-based company said today in a statement. In September, Cytokinetics reported that its experimental therapy for acute heart failure failed to help people breathe more easily in a clinical trial.

“It’s pretty negative news,” Chad Messer, an analyst with Needham & Co Inc., said in a telephone interview from New York. “People are going to sell and run away, they’re going to consider it dead money for a while. I think there’s a fair amount of value left in the company.”

Messer said the company’s heart disease drug may show more positive trial results by year’s end.

To contact the reporter on this story: Sonali Basak in New York at sbasak7@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Bruce Rule, Andrew Pollack

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.